incyte.com — August 2026 traffic, keywords & AI visibility

Search engines send incyte.com an estimated 23,500 visits a month. Effectively all of it is organic — about 23,500 visits from unpaid results. Spread across 1,402 ranking keywords, that averages roughly 17 organic visits per keyword.

incyte.com scores 89 out of 100 on our AI visibility scale, grade A. It takes full marks for LLMS.txt and Structured data. The biggest gap is Crawlability, at 5 of 10 points (robots ✓ · sitemap ✗), worth 5 points if closed. It also loses points on Company profile (22/25) and SEO health (17/20).

The llms.txt on incyte.com runs to 81 lines (4,622 characters) across 12 sections, last generated in May 2026. It introduces the site as "Incyte Corporation - Innovative Biopharmaceutical Solutions". It tells AI engines the business works in Biopharmaceuticals, Drug Development, Clinical Trials and Oncology. It describes 5 products, including Jakafi, Opzelura and Pemazyre. Services it lists include Clinical Trial Participation, Patient Access Support, Drug Development Partnerships and Precision Medicine Consulting. The audience it names is Patients with cancer, inflammatory conditions, aged Adults (Global). Technologies it mentions include HTTPS, Viewport Meta and Robots.txt. The keywords it claims start with "Incyte", "Incyte Corporation", "Incyte Pharmaceuticals" and "biopharmaceuticals". It gives the company type as Public.

# Incyte Corporation - Innovative Biopharmaceutical Solutions

## About
Incyte Corporation is a biopharmaceutical powerhouse specializing in the discovery, development, and delivery of innovative small molecule drugs. They target serious unmet needs in oncology, dermatology, and inflammatory diseases with a pipeline boasting multiple late-stage candidates. From their origins in genomics, Incyte has evolved into a commercial-stage company with blockbuster products like Jakafi leading the charge against myeloproliferative neoplasms. Clinical trials form the backbone of their operations, with rigorous phase studies ensuring safety and efficacy before market launch. Patient support initiatives bridge the gap between therapy and real-world application, offering resources for access and adherence. Strategic alliances amplify their R&D, partnering with global leaders to co-develop assets. Incyte's focus on precision medicine leverages biomarkers for tailored treatments, enhancing outcomes in complex diseases. Their Wilmington headquarters buzzes with scientists pushing boundaries in kinase inhibitors and beyond. Commercial efforts span major markets, prioritizing patient-centric commercialization. As biopharma innovators, they navigate regulatory landscapes adeptly, securing approvals that change lives. Incyte invests in emerging areas like immuno-oncology, promising future pipeline s

Google lists incyte.com for about 1,402 keywords, which together bring an estimated 23,500 organic visits a month.

The latest technical audit of incyte.com scored 90 out of 100 overall. SEO is its weakest area at 85, while accessibility scores highest at 90. The audit makes 12 recommendations in all, and 3 of the 4 listed first are rated high priority or critical.

Incyte Corporation's company profile names https://www.amgen.com, https://www.bms.com, https://www.gilead.com and https://www.abbvie.com as competitors. Its own llms.txt adds https://www.merck.com and https://www.eli-lilly.com. Outside its market, the domains ranked closest to it in our worldwide ranking are il.gov, underarmour.co.jp, eknjizara.hr and whatfinger.com.

https://www.amgen.com

https://www.bms.com

https://www.gilead.com

https://www.abbvie.com

https://www.merck.com

https://www.eli-lilly.com